Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease

Dijk, Karin D. van; Jongbloed, Wesley; Heijst, Johannes A.; Teunissen, Charlotte E.; Groenewegen, Henk J.; Berendse, Henk W.; Berg, Wilma D. J. van de; Veerhuis, Robert

doi:10.1016/j.parkreldis.2013.07.016

Cited by 26 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased risk for developing cognitive impairment and dementia of PD patients in comparison with the general population makes it reasonable to link AD markers such as Aβ42 to PDD. Several studies have shown similar (Holmberg et al, 2003; Mollenhauer et al, 2006; Ohrfelt et al, 2009; Přikrylová Vranová et al, 2010; Aerts et al, 2011; Parnetti et al, 2011; van Dijk et al, 2013a) or decreased (Sjögren et al, 2002; Compta et al, 2009b; Mollenhauer et al, 2011; Shi et al, 2011; Kang et al, 2013; Nutu et al, 2013a; Vranová et al, 2014) CSF Aβ1-42 (Aβ1-42) in PD patients, with the exception of one study which reports increased levels (Parnetti et al, 2014b). Other found decreased CSF Aβ-1-42 (Mollenhauer et al, 2006; Compta et al, 2009b; Alves et al, 2010; Montine et al, 2010; Siderowf et al, 2010) and Aβ1-40 (Alves et al, 2010) and Aβ1-38 (Alves et al, 2010) only in PDD patients or in PD patients with memory impairment.…”

Section: Proteins Involved In the Pathogenesis Of Parkinson's Diseasementioning

confidence: 82%

“…Many studies have shown similar CSF total tau and phosphorylated tau (phospho tau ) in PD patients to controls (Blennow et al, 1995; Molina et al, 1997c; Jansen Steur et al, 1998; Sjögren et al, 2002; Mollenhauer et al, 2006; Parnetti et al, 2008, 2011, 2014a,b; Ohrfelt et al, 2009; Compta et al, 2009b; Alves et al, 2010; Montine et al, 2010; Aerts et al, 2011; van Dijk et al, 2013a; Herbert et al, 2014). Several of these studies have shown increased CSF tau in demented PD patients (Mollenhauer et al, 2006; Compta et al, 2009b).…”

Section: Proteins Involved In the Pathogenesis Of Parkinson's Diseasementioning

confidence: 99%

“…CSF levels of clusterin have been reported to be increased (Přikrylová Vranová et al, 2010; Vranová et al, 2014) or normal (van Dijk et al, 2013a), tissue transglutaminase (Vermes et al, 2004) increased in PD, and cystatin C normal in PD (Přikrylová Vranová et al, 2010; Yamamoto-Watanabe et al, 2010) and decreased in MSA (Yamamoto-Watanabe et al, 2010). …”

Section: Proteins Involved In the Pathogenesis Of Parkinson's Diseasementioning

confidence: 99%

See 2 more Smart Citations

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds from the brain back to the bloodstream. In several neurodegenerative diseases, including Parkinson's disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with the aim of establishing useful biomarkers for an accurate differential diagnosis among these syndromes. This review article summarizes the studies reported on CSF levels of many potential biomarkers of PD. The most consistent findings are: (a) the possible role of CSF urate on the progression of the disease; (b) the possible relations of CSF total tau and phosphotau protein with the progression of PD and with the preservation of cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a useful marker of further cognitive decline in PD patients, and (d) the potential usefulness of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with long-term follow-up and neuropathological confirmation would be useful in establishing appropriate biomarkers for PD.

show abstract

Section: Proteins Involved In the Pathogenesis Of Parkinson's Diseasementioning

confidence: 82%

Section: Proteins Involved In the Pathogenesis Of Parkinson's Diseasementioning

confidence: 99%

Section: Proteins Involved In the Pathogenesis Of Parkinson's Diseasementioning

confidence: 99%

See 1 more Smart Citation

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…There is no consistent association of total CSF apoE or apoJ protein concentration and the diagnosis of MCI, AD dementia, or PD (7–10, 12–16, 27, 37, 38, 61, 129). Here, neither concentration nor size distribution of apoE-positive or apoJ-positive particles in CSF was associated with a diagnosis of MCI or AD dementia, or with PD.…”

Section: Discussionmentioning

confidence: 98%

“…CSF apoJ may be a biomarker of pre-dementia stages of AD (36). CSF clusterin concentration has not been associated reproducibly with PD (27, 37, 38). …”

Section: Introductionmentioning

confidence: 96%

Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

Yang

Keene

Peskind

et al. 2015

J Neuropathol Exp Neurol

View full text Add to dashboard Cite

Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ- and amyloid (A) β42-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE ε4/ε4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level vs. those in APOE ε3/ε3 or APOE ε3/ε4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. CSF apoE-positive and β-amyloid (Aβ42)-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients vs. age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.

show abstract

Association of CLU gene polymorphism with Parkinson's disease in the Chinese Han population

Lin

Lü

Zhou

et al. 2020

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: Clusterin (CLU) plays important role in the pathology of neurodegenerative disorders. Recently, a genetic variant of CLU rs9331896 has been reported as a risk estimate for Alzheimer's disease (AD). However, the association between this variant and the risk of Parkinson's disease (PD) in the Chinese Han population remains elusive. Methods: We sequenced CLU rs9331896 in 353 PD patients and 326 healthymatched individuals of the Chinese Han population. The genotypes of rs9331896 were analyzed using MassArray (Agena Bioscience, San Diego, CA, USA) in accordance with the manufacturer's instructions. The distribution of genotypes and allelic frequencies was analyzed by a chi-squared test. Additionally, the expression of CLU protein in plasma was evaluated by an enzyme-linked immunosorbent assay and analysed with a t-test. Results: The TT genotype in rs9331896 in a recessive model was found to be associated with the increased risk of PD (odds ratio = 1.408, 95% confidence interval = 1.034-1.916, p = 0.029). Subgroup analysis indicated that TT genotype carriers showed a significantly higher risk in male PD patients compared to male healthy controls (odds ratio = 1.611, 95% confidence interval = 1.046-2.483, p = 0.030). In addition, CLU levels in the plasma of PD patients were significantly higher than controls (p = 0.024). Conclusions: The CLU-rs9331896-TT genotype was a risk factor for PD, particularly in males. PD patients also expressed a high level of CLU in plasma.

show abstract

Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease

Cited by 26 publications

References 27 publications

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

Association of CLU gene polymorphism with Parkinson's disease in the Chinese Han population

Contact Info

Product

Resources

About